Tenderwize
Retour à la recherche

Open House Original Discount Agreements 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 430 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (Wirkstoffkombination)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed purchase volumes; revenue depends on market uptake.

Legal recourse is to social courts, not procurement review bodies; may be unfamiliar.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclusion of discount agreements for the supply of Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid (HIV drug combination) to TK and participating insurance funds.
  • Contractual terms are non-negotiable and uniform for all participants.
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) to conclude discount agreements (Rabattverträge) for the active ingredient combination Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid. All eligible pharmaceutical entrepreneurs can join at any time during the contract period. No competitive selection; contracts are concluded with all meeting the eligibility criteria. Contract duration max 24 months from 01.11.2025 to 31.10.2027, with early termination upon patent expiry. No estimated value provided.

Risques

No guaranteed purchase volumes; revenue depends on market uptake.

Legal recourse is to social courts, not procurement review bodies; may be unfamiliar.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered drug.
  • Must hold a valid marketing authorization for the drug combination or be entitled to place it on the market.
  • Must have seat in Germany, another EU Member State, or EEA state (§9 Abs. 2 AMG).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No competitive award; contract concluded with all eligible pharmaceutical entrepreneurs.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Original Discount Agreements 2025-25 - Darunavir/Cobicistat/Emtricitabin/Tenofovir alafenamid

Single lot for discount agreements on the specified HIV drug combination. Open to all eligible pharmaceutical entrepreneurs. No exclusivity, uniform conditions.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2025 - Oct 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No competitive award; contract concluded with all eligible pharmaceutical entrepreneurs.

Date limite

Deadline Oct 30, 2027

Détails de la procédure

Date de publication
21 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
548037-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3